Tumor resistance and toxicity to normal tissues limit the efficacy of conventional anticancer treatments such as radiation and chemotherapy. The systemic side effects of chemotherapy in particular represent a severe problem. The most promising alternative to conventional therapy is targeted tumor therapy in which selective molecules are used to direct anticancer drugs to the tumor, thereby limiting the damage to healthy tissue. For targeted tumor therapy, peptides and antibodies possess a key position as drug delivery vectors . To kill the targeted tumor cells, the favorable targeting properties of antibodies and peptides must be combined with an efficient cytotoxic moiety such as toxins, drugs, or therapeutic radioactive nuclides. Targeted radionuclide therapy (TRT) uses the latter as a local source of radiation to combine the favorable targeting properties of peptides and antibodies with the effectiveness of radiation-induced cell death [2,3]. A major advantage of TRT is the possibility to determine the selective accumulation in the targeted tissue by molecular imaging studies via single photon computed tomography (SPECT) or positron emission tomography (PET) using structurally identical diagnostic compounds. For this purpose, targeting of epitopes that are expressed even in relatively low concentrations is feasible. These noninvasive imaging methods allow estimation of radiation dose distribution prior to therapy, tumor staging, and early monitoring of the efficacy of individual treatments. This novel class of pharmaceuticals offers the potential to develop patient-specific therapies based on the new ‘image and treat’ approach.
The current treatment options for advanced urologic cancers demonstrate limited efficacy and severe side effects [4••,5•,6••,7]. Therefore, there is a need for new therapeutic strategies. The idea of individualizing therapies to obtain optimal clinical results is not new but has only recently been applied to urological malignancies. This review focuses on the recent advances of molecular imaging as applied to TRT in uro-oncology.
Molecular imaging and targeted radionuclide therapy
In recent years, there has been much focus on personalized medicine, wherein pharmaceutical therapies are tailored to the particular characteristics of the individual patient. The role of molecular imaging in personalized medicine, using targeted drugs in oncology, is very attractive. It provides in-vivo regional information before and, in real time, during treatment, which cannot be obtained by in-vitro methods (‘regional proteomics’). In clinical practice, imaging biomarkers may be used to screen for cancer, confirm diagnosis, assess extent, and predict response to available therapies . Nuclear medicine plays an important role in establishing imaging biomarkers in clinical decision-making. 18F-fluorodeoxyglucose (FDG), the first PET molecular imaging biomarker, is a biomarker of glucose metabolism. Most cancer cell types demonstrate increased glucose metabolism leading to increased 18F-FDG uptake. 18F-FDG PET/CT is now widely used in the management of several cancer types. In uro-oncology, PET/CT has been one of the slowest areas to develop. This is mainly due to urinary excretion of 18F-FDG and low 18F-FDG uptake, especially in prostate and some renal cancers. However, the role of PET/CT in uro-oncology is likely to expand as new and more favorable tracers are evaluated . New biomarkers that image cell proliferation, apoptosis, angiogenesis, hypoxia, and growth factor receptors are being studied  and may lead to enhanced clinical management of cancer patients.
Radiolabeling of modified forms of the imaging biomolecules with therapeutic radionuclides allows therapeutic applications using radioconjugates that are almost identical to the imaging probes. In contrast to chemotherapy, TRT requires very low mass amounts of the targeting compound. Peptide receptor radiation therapy (PRRT), as one form of TRT, is based on site-specific accumulation, preferentially due to receptor-mediated endocytosis and intracellular retention of radiolabeled peptides [10,11]. At present, PRRT is mainly used for the treatment of neuroendocrine tumors . The somatostatin receptor-binding agents 90Y-DOTATOC and 177Lu-DOTATATE are examples of successfully applied oncological PRRTs [2,3,13••]. In radioimmunotherapy (RIT), antibodies are labeled with radionuclides for therapy. 90Y-rituximab (Zevalin; Biogen Idec, Cambridge, Massachusetts, USA) and 131I-tositumomab (Bexxar; Corixa, Seattle, Washington, USA) are examples of radiolabeled antibodies for cancer treatment [13••]. These two therapeutic agents target the CD20 antigen on B cells.
The therapeutic effect of TRT is achieved primarily by ionizing radiation of the radionuclide, and the therapeutically effective radiation dose is determined by the physical characteristics of the radionuclide. As the radiation is not restricted to the targeted cell, it may also affect all tumor cells in its range. This effect, called ‘bystander’ or ‘crossfire’ effect, is particularly important for treatment of tumors with heterogeneous antigen or receptor expression or insufficient vascularization . The most common nuclides that are currently used for endoradiotherapy are β-emitters such as 131I, 177Lu, and 90Y. Medium-energy β-emitters, that is, 131I and 177Lu, are more effective for the treatment of small tumors [2,3]. In larger tumors, isotopes emitting high-energy β-radiation, like 90Y, might present a better alternative. Molecular imaging plays an essential role in balancing the clinical benefits and risks of TRT. To effectively treat individual patients, careful assessment of biodistribution, dosimetry, and toxicity of the therapeutic radionuclide is essential.
Carbonic anhydrase IX
Renal cell carcinoma (RCC) is the third most common genitourinary cancer site after prostate and bladder cancer [14•]. Imaging plays an important role in the clinical management of RCC [15••]. However, RCC is a radiation-resistant and chemotherapy-resistant tumor, and current treatments have limited efficacy, resulting in high morbidity and mortality in patients with metastatic disease [4••]. Thus, there is a need for new therapeutic strategies in RCC. Monoclonal antibodies targeting tumor-associated antigens have been developed for RCC [4••,16], and targeted agents are being used increasingly for the treatment of metastatic RCC [17,18]. Among them, targeting of carbonic anhydrase IX (CAIX) antigen using monoclonal chimeric G250 antibody (cG250) is a new approach for imaging and treating RCC. CAIX is ubiquitously expressed in more than 90% of clear-cell RCC (ccRCC) but not in normal kidney [16,19–21]. In addition, high expression of CAIX appears to be a marker of poor prognosis in ccRCC [20,22].
The antibody G250 has been studied in ccRCC both as a murine antibody and a chimeric antibody (cG250) . For molecular imaging, radiolabeled cG250 demonstrates excellent visualization of known metastatic lesions and frequently also detects new lesions in patients [24–28]. Recently, 124I-cG250 has been used for evaluating RCC. Divgi et al.  assessed whether 124I-cG250 PET could predict for ccRCC in 26 patients with renal masses. Surgery was scheduled 1 week after 124I-cG250 infusion. PET/CT scanning was performed within 3 h before surgery. In this series, 124I-cG250 PET accurately identified 15 of 16 ccRCC, and all nine nonclear-cell renal masses were negative for the tracer. The sensitivity of 124I-cG250 PET was 94%, the negative predictive value was 90%, and specificity and positive predictive accuracy were both 100%. Currently, a multicenter trial with a larger group of patients is being conducted to evaluate the role of 124I-cG250 PET/CT in patients with renal masses . 124I-cG250 PET/CT may be a valuable tool for diagnosing metastases in patients with a G250-positive primary tumor and/or for the differential diagnosis of suspect kidney lesions, that is, distinguishing ccRCC from other subtypes. Preoperative identification of tumor type could have important implications for the choice of treatment.
CAIX is associated with hypoxia, and expression of CAIX is regulated by the hypoxia-inducible factor 1α (HIF-1α) . Recently, Lawrentschuk et al. [30••] used in-vivo studies for investigation of hypoxia and CAIX expression in a RCC xenograft model with oxygen tension measurements and 124I-cG250 PET/CT. 124I-cG250 PET/CT demonstrated excellent tumor targeting, and a correlation between tracer uptake, as measured by standard uptake value (SUV) on noninvasive PET/CT studies, and traditional biodistribution studies was demonstrated. However, no significant correlation between CAIX and hypoxia was found.
The first G250 investigated for RIT in ccRCC were murine antibodies, which can cause an immune response in humans. The production of human antimouse antibodies (HAMAs) inhibits the effectiveness of the second administered dose of radiolabeled antibody . In a phase I/II RIT study, escalating activity doses of 131I-G250 were administered to patients with metastatic RCC . Seventeen out of 33 patients showed stabilization of disease progression. However, all the patients developed a HAMA response. After development of the chimeric form of G250, 131I-cG250 was tested in clinical trials [25,32,33]. The maximum tolerated dose (MTD) of 131I-cG250 was determined in a phase I trial in patients with advanced metastatic RCC . The MTD was determined to be 2220 MBq/m2, with hematological toxicity being the dose-limiting factor. Divgi et al.  performed fractionation of the dose in a phase I study. Brouwers et al.  investigated the effect of two sequential high doses of 131I-cG250. Five of the 19 patients evaluated had stabilization of their disease, lasting 3–12 months. However, no partial or complete responses were seen.
Radionuclides other than 131I may enhance the therapeutic index of radiolabeled cG250. In order to optimize cG250 RIT, the therapeutic properties of cG250 labeled with four different radionuclides were tested in mice with ccRCC xenografts . The results of the in-vivo study indicated that 177Lu-cG250 and 90Y-cG250 conjugates may be superior for RIT compared with 131I conjugates. Currently, a phase I/II trial is ongoing, investigating the efficacy of 177Lu-DOTA-cG250 in patients with advanced RCC (NCT00142415). Preliminary results demonstrate excellent tumor targeting of RCC lesions and indicate that 177Lu-cG250 treatment can stabilize previously progressive metastatic RCC .
Prostate-specific membrane antigen
Prostate cancer is the most common cancer in US men and is the second leading cause of cancer death among men in the United States [36•]. Imaging is important in the clinical management of prostate cancer patients [37••]. Treatments range from surveillance to radical local treatment to androgen-deprivation therapy . As there are no effective treatments for advanced prostate cancer, new strategies have to be considered [36•]. Several cell surface proteins, glycoproteins, receptors, enzymes, and peptides have been proposed as potential targets for the treatment of prostate cancer [38,39]. Among these, the prostate-specific membrane antigen (PSMA) represents an attractive target for molecular imaging and therapy [40•]. PSMA is specifically expressed on prostate epithelial cells and is strongly upregulated in prostate cancer, with highest expression occurring in androgen insensitive or metastatic disease [41•]. PSMA is not secreted or released into the circulation unlike prostate-specific antigen (PSA), which makes it an excellent target for diagnostic and therapeutic agents.
Prostate-specific membrane antigen imaging
The first commercial monoclonal antibody (mAb) against PSMA was 7E11, which is used in the Food and Drug Administration (FDA)-approved 111In-CYT-356-based imaging of prostate cancer (ProstaScint) . The 7E11 antibody targets an intracellular epitope of PSMA and, therefore, binds only to permeabilized necrotic cells [41•]. Another anti-PSMA mAb, J591, which binds to an epitope on the extracellular domain of PSMA , presents a better alternative for targeting of prostate cancer. J591 had been extensively studied in preclinical models and demonstrated high tumor-to-normal tissue ratios in prostate cancer xenografts [44,45]. These studies were followed by several clinical trials using J591 labeled with different nuclides for radioimmunoscintigraphy and RIT [46–48] that confirmed the feasibility of J591 as a prostate cancer-targeting agent (see PSMA RIT below).
Recently, other mAbs that target PSMA for molecular imaging have been developed. Elsasser-Beile et al.  reported the development of three IgG mAbs (3/A12, 3/E7, and 3/F11) with affinity for PSMA. Wolf et al. [50•] demonstrated that 3/A12, 3/E7, and 3/F11 bind to different extracellular epitopes of PSMA. Elsasser-Beile et al. [51•] used 64Cu-3/A12 for PET imaging in a prostate cancer xenograft model. PET was performed 3, 24, and 48 h after injection of 64Cu-3/A12, and good tumor-to-background ratio was found. PSMA-negative tumors were negative on PET. Low-molecular-weight, radiopharmaceutical-based imaging agents may provide superior pharmacokinetics for imaging than radiolabeled antibodies characterized by long circulation time and delayed clearance from nontarget tissues . Recently, low-molecular-weight agents that target or inhibit PSMA have demonstrated promising results [53–56,57••]. Foss et al.  showed successful imaging of xenografts that express PSMA using PET and the radiolabeled PSMA inhibitor N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-S-[11C]methyl-l-cysteine (DCMC). Mease et al.  extended that work by preparing and testing a PSMA inhibitor of the same class labeled with 18F. Biodistribution and imaging studies showed high uptake of 18F-DCFBC in the PSMA-positive tumors with little to no uptake in PSMA-negative tumors. Hillier et al. [57••] reported that two small molecule inhibitors targeting PSMA, MIP-1072 and MIP-1095, exhibited high affinity for PSMA. The uptake of 123I-MIP-1072 and 123I-MIP-1095 in prostate cancer xenografts was shown by SPECT/CT.
Prostate-specific membrane antigen radioimmunotherapy
Prostate cancer represents an attractive target for RIT for several reasons: the prostate gland is a nonvital organ, thereby allowing targeting of tissue-specific antigens; metastases from prostate cancer are mainly localized in lymph nodes and bones, locations with good access to circulating antibodies; the metastases are often small enough to ensure good antibody penetration; and the serum marker PSA can be used for monitoring of therapeutic efficacy [40•,41•,42,58]. In RIT, myelotoxicity due to bone marrow radiation-absorbed doses (Bmrad) is frequently the dose-limiting factor that determines the MTD. In a dose-escalation study, prostate cancer patients (n = 28) were treated with either 90Y-labeled or 177Lu-labeled J591 antibodies . Myelotoxicity after treatment with 177Lu-J591 could be predicted on the basis of the radioactive dose administered or the Bmrad. In contrast, no correlation between myelotoxicity and 90Y-J591 dose was found. In a phase I trial, the MTD of 177Lu-J591 was found to be 70 mCi/m2 in advanced prostate cancer patients . Multiple doses of 30 mCi/m2 were well tolerated, and excellent targeting of known metastases was demonstrated.
In a recent study by Pandit-Taskar et al. , 14 patients with metastatic prostate cancer received escalating doses of 111In-J591 in a series of administrations, each separated by 3 weeks. 111In-J591 correctly localized 93.7% of the bone lesions detected by conventional imaging. In this study, the optimal antibody mass for RIT was determined to be greater than or equal to 50 mg. Recently, Tagawa et al.  showed in a phase II trial that a single dose of 177Lu-J591 was well tolerated and with reversible myelosuppression. In this trial, antitumor activity was demonstrated in patients with advanced metastatic castrate-resistant prostate cancer, and excellent targeting of known sites of metastases was seen in 97% (31/32) of the patients.
Overexpression of the HER2 protein and amplification of the HER2 gene have been implicated in tumor development, progression, and poor prognosis in several types of cancers . There is increasing evidence that HER2 also plays a role in advanced prostate cancer [62–64] and bladder cancer [65,66]. In prostate cancer patients, HER2 expression is associated with disease progression and androgen independence [62,63], and preoperative plasma HER2 is associated with cancer progression after prostatectomy [62,64]. Caner et al.  found that 61.1% of high-grade urothelial carcinomas demonstrated HER2 overexpression. Recently, Lae et al.  demonstrated in a large study (n = 1005) that 9.2% of invasive bladder carcinomas are HER2-positive. Therefore, HER2 represents a potential target for both molecular imaging and therapy in HER2-positive bladder and prostate cancers.
Monoclonal antibodies such as trastuzumab and pertuzumab, or small scaffold Affibody molecules, are used as HER2-targeting agents . For imaging purposes, these agents are labeled with positron-emitting or gamma-emitting radionuclides for PET or SPECT imaging, respectively [61,68••,69–71,72•,73]. There is increasing evidence that Affibody molecules or other small nonimmunoglobulin-based tracers have the best potential for developing high-contrast imaging agents to visualize HER2 in vivo compared with full-length monoclonal antibodies [61,72•]. Kramer-Marek et al.  have radiolabeled a HER2-binding Affibody molecule with 18F for in-vivo monitoring of HER2 expression by PET. Recently, Kramer-Marek et al. [74••] also demonstrated that the same tracer can be used for PET/CT imaging to assess changes in HER2 expression following therapeutic intervention. Baum et al.  used HER2 Affibody molecules labeled with 111In or 68Ga and demonstrated high-quality SPECT and PET/CT imaging of HER2-positive xenografts. This approach allowed detection of even very small malignant lesions. Cheng et al.  also found PET imaging of HER2 expression promising in a xenograft tumor model. Currently, an ongoing trial is evaluating the role of 111In-CHX-A DTPA trastuzumab imaging for HER2 expression in breast cancer patients (NCI-07-C-0101).
HER2 radionuclide therapy
For therapy, the targeting vector (trastuzumab, Affibody molecules) has been labeled with radionuclides suitable for therapy [72•,76,77•,78,79]. Tolmachev et al.  labeled a HER2-specific Affibody molecule with 177Lu for radionuclide therapy of HER2-positive microxenografts. The results indicate that HER2 RIT may be promising for the treatment of HER2-expressing malignant micrometastases. This strategy, involving assessment of target presence (HER2-positive cancer) and distribution in an individual patient, followed by optimized HER2-specific radionuclide drug delivery, has the potential to improve therapeutic outcome of HER2-positive cancers while reducing side effects.
The aim of today's state of the art molecular imaging is detection of the very early stages of cancer, followed by therapeutic action. Molecular imaging may provide unique means for the selection of patients who may benefit from targeted therapies, as well as allow monitoring of early responses to treatment and enable subsequent restaging. A considerable amount of effort has been focused on the development of personalized medicine in oncology. In recent years, tumor-specific biomarkers have proven to be potentially useful in the development of new therapeutic strategies in uro-oncology. However, considerable investments in research are still required for personalized medicine to be fully developed and implemented clinically.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 299).
1 Brissette R, Prendergast JK, Goldstein NI. Identification of cancer targets and therapeutics using phage display. Curr Opin Drug Discov Devel 2006; 9:363–369.
2 Wangler C, Buchmann I, Eisenhut M, et al
. Radiolabeled peptides and proteins in cancer therapy. Protein Pept Lett 2007; 14:273–279.
3 Boerman OC, Koppe MJ, Postema EJ, et al
. Radionuclide therapy of cancer with radiolabeled antibodies. Anticancer Agents Med Chem 2007; 7:335–343.
4•• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373:1119–1132.
5• Bischoff CJ, Clark PE. Bladder cancer. Curr Opin Oncol 2009; 21:272–277.
6•• Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239–249.
7 Damber JE, Aus G. Prostate cancer. Lancet 2008; 371:1710–1721.
8 Carrio I. Key role of nuclear medicine in bringing imaging biomarkers into clinical practice. Eur J Nucl Med Mol Imaging 2009; 36:1937–1939.
9 Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008; 179:34–45.
10 Oyen WJ, Bodei L, Giammarile F, et al
. Targeted therapy in nuclear medicine: current status and future prospects. Ann Oncol 2007; 18:1782–1792.
11 Haberkorn U, Eisenhut M, Altmann A, Mier W. Endoradiotherapy with peptides: status and future development. Curr Med Chem 2008; 15:219–234.
12 de JM, Breeman WA, Kwekkeboom DJ, et al
. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res 2009; 42:873–880.
13•• Zoller F, Eisenhut M, Haberkorn U, Mier W. Endoradiotherapy in cancer treatment: basic concepts and future trends. Eur J Pharmacol 2009; 625:55–62.
14• Garcia JA, Cowey CL, Godley PA. Renal cell carcinoma. Curr Opin Oncol 2009; 21:266–271.
15•• Choudhary S, Sudarshan S, Choyke PL, Prasad SR. Renal cell carcinoma: recent advances in genetics and imaging. Semin Ultrasound CT MR 2009; 30:315–325.
16 Stillebroer AB, Oosterwijk E, Oyen WJ, et al
. Radiolabeled antibodies in renal cell carcinoma. Cancer Imaging 2007; 7:179–188.
17 Patard JJ, Pouessel D, Bensalah K, Culine S. Targeted therapy in renal cell carcinoma. World J Urol 2008; 26:135–140.
18 Oosterwijk E, Boerman OC, Oyen WJ, et al
. Antibody therapy in renal cell carcinoma. World J Urol 2008; 26:141–146.
19 Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al
. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986; 38:489–494.
20 Oosterwijk E. Carbonic anhydrase IX: historical and future perspectives. BJU Int 2008; 101(Suppl 4):2–7.
21 Jensen HK, Nordsmark M, Donskov F, et al
. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. BJU Int 2008; 101(Suppl 4):41–44.
22 Belldegrun AS, Bevan P. Carbonic anhydrase IX: role in diagnosis, prognosis and cancer therapy. Introduction. BJU Int 2008; 101(Suppl 4):1.
23 Perini R, Pryma D, Divgi C. Molecular imaging of renal cell carcinoma. Urol Clin North Am 2008; 35:605–611.
24 Steffens MG, Boerman OC, de Mulder PH, et al
. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5:3268s–3274s.
25 Brouwers AH, Mulders PF, de Mulder PH, et al
. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol 2005; 23:6540–6548.
26 Brouwers AH, Buijs WC, Oosterwijk E, et al
. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res 2003; 9:3953S–3960S.
27 Brouwers AH, Mulders PF, Oyen WJ. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. J Clin Oncol 2008; 26:3808–3809.
28 Divgi CR, Pandit-Taskar N, Jungbluth AA, et al
. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8:304–310.
29 Pastorekova S, Ratcliffe PJ, Pastorek J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int 2008; 101(Suppl 4):8–15.
30•• Lawrentschuk N, Lee FT, Jones G, et al
. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT. Urol Oncol 2009, June 11 [Epub ahead of print]. PET studies demonstrating excellent localization of 124
I-cG250 in tumors in a human RCC xenograft model.
31 Divgi CR, Bander NH, Scott AM, et al
. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4:2729–2739.
32 Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al
. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15:1529–1537.
33 Divgi CR, O’Donoghue JA, Welt S, et al
. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004; 45:1412–1421.
34 Brouwers AH, van Eerd JE, Frielink C, et al
. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 2004; 45:327–337.
35 Stillebroer AB, Oosterwijk E, Mulders PF, et al
. Radioimmunotherapy with luthetium-177 labeled monoclonal antibody cG250 in patients with advanced renal cell carcinoma [abstract]. Cancer Biother Radiopharm 2008; 23:523–524.
36• Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009; 21:260–265.
37•• Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 2009; 192:1471–1480.
38 Ross JS, Gray KE, Webb IJ, et al
. Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev 2005; 24:521–537.
39 Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 2009; 48:193–199.
40• Bouchelouche K, Capala J, Oehr P. Positron emission tomography/computed tomography and radioimmuotherapy of prostate cancer. Curr Opin Oncol 2009; 21:469–474. The review focuses on recent advancements in PET/CT and RIT of prostate cancer.
41• Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009; 10:118–125. The review provides an overview of the new strategies with targeted therapies for prostate cancer against the PSMA.
42 Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 2004; 48:297–304.
43 Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al
. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000; 60:5237–5243.
44 McDevitt MR, Barendswaard E, Ma D, et al
. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60:6095–6100.
45 Smith-Jones PM, Vallabhajosula S, Navarro V, et al
. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 2003; 44:610–617.
46 Olson WC, Heston WD, Rajasekaran AK. Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2007; 2:182–190.
47 Tagawa S, Jeske S, Milowski MI, et al
. Phase II trial of 177Lutetium radiolabeled antiprostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients with metastatic castrate-resistant prostate cancer [abstract]. Cancer Biother Radiopharm 2008; 23:525.
48 Pandit-Taskar N, O’Donoghue JA, Morris MJ, et al
. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008; 49:1066–1074.
49 Elsasser-Beile U, Wolf P, Gierschner D, et al
. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006; 66:1359–1370.
50• Wolf P, Freudenberg N, Buhler P, et al
. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate 2009 Nov 24. [Epub ahead of print]. Three new antibodies binding to different extracellular PSMA epitopes.
51• Elsasser-Beile U, Reischl G, Wiehr S, et al
. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009; 50:606–611.
52 Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23:1137–1146.
53 Mease RC, Dusich CL, Foss CA, et al
. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 2008; 14:3036–3043.
54 Foss CA, Mease RC, Fan H, et al
. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005; 11:4022–4028.
55 Chen Y, Foss CA, Byun Y, et al
. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 2008; 51:7933–7943.
56 Banerjee SR, Foss CA, Castanares M, et al
. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008; 51:4504–4517.
57•• Hillier SM, Maresca KP, Femia FJ, et al
. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69:6932–6940.
58 Jakobovits A. Monoclonal antibody therapy for prostate cancer. Handb Exp Pharmacol 2008; 181:237–256.
59 Vallabhajosula S, Goldsmith SJ, Hamacher KA, et al
. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 2005; 46:850–858.
60 Bander NH, Milowsky MI, Nanus DM, et al
. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23:4591–4601.
61 Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008; 14:2999–3019.
62 Shariat SF, Bensalah K, Karam JA, et al
. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res 2007; 13:5377–5384.
63 Shi Y, Brands FH, Chatterjee S, et al
. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001; 166:1514–1519.
64 Domingo-Domenech J, Fernandez PL, Filella X, et al
. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol 2008; 19:269–275.
65 Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol 2008; 130:274–281.
66 Lae M, Couturier J, Oudard S, et al
. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2009 Nov 4. [Epub ahead of print]
67 Caner V, Turk NS, Duzcan F, et al
. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008; 14:261–266.
68•• McLarty K, Cornelissen B, Cai Z, et al
. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009; 50:1340–1348.
69 Ahlgren S, Wallberg H, Tran TA, et al
. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant Affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 2009; 50:781–789.
70 Smith-Jones PM, Solit D, Afroze F, et al
. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 2006; 47:793–796.
71 Cheng Z, De Jesus OP, Namavari M, et al
. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008; 49:804–813.
72• Orlova A, Wallberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled Affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50:417–425.
73 Kramer-Marek G, Kiesewetter DO, Martiniova L, et al
. [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008; 35:1008–1018.
74•• Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18F-labeled Affibody molecules. J Nucl Med 2009; 50:1131–1139. The study demonstrates that 18
F-labeled Affibody molecules are useful for PET imaging of HER2 that allows monitoring of expression levels and quantification of possible changes in receptor expression due to therapeutic intervention and, thereby, may provide means for early assessment of tumor response.
75 Baum R, Orlova A, Tolmachev V, Feldwisch J. A novel molecular imaging agent for diagnosis of recurrent HER2 positive breast cancer. First time in human study using Indium-111- or Galium-68-labelled Affibody molecule [abstract]. Eur J Nucl Med Mol Imaging 2006; 33:S91.
76 Tolmachev V, Orlova A, Pehrson R, et al
. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007; 67:2773–2782.
77• Orlova A, Tran TA, Ekblad T, et al
. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Eur J Nucl Med Mol Imaging 2009 Sep 22. [Epub ahead of print] Rhenium-labeled Affibody molecules are potential radiotherapeutic agents for radionuclide therapy of HER2-positive tumors.
78 Ballangrud AM, Yang WH, Palm S, et al
. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 2004; 10:4489–4497.
79 Costantini DL, Bateman K, McLarty K, et al
. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med 2008; 49:1498–1505.